135 related articles for article (PubMed ID: 12670354)
1. Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma.
Younis TH; Alam A; Paplham P; Spangenthal E; McCarthy P
Br J Haematol; 2003 Apr; 121(1):191-2. PubMed ID: 12670354
[No Abstract] [Full Text] [Related]
2. Role of thalidomide in the treatment of patients with multiple myeloma.
Morgan GJ; Davies FE
Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S14-22. PubMed ID: 23827438
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide in multiple myeloma: state of art.
Tosi P; Cavo M
Haematologica; 2002 Mar; 87(3):233-4. PubMed ID: 11869932
[No Abstract] [Full Text] [Related]
4. Thalidomide treatment for immunoglobulin D multiple myeloma in a patient on chronic hemodialysis.
Hayashi T; Yamaguchi I; Saitoh H; Takagi M; Nonaka Y; Nomura T
Intern Med; 2003 Jul; 42(7):605-8. PubMed ID: 12879955
[TBL] [Abstract][Full Text] [Related]
5. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.
Cavo M; Zamagni E; Tosi P; Cellini C; Cangini D; Tacchetti P; Testoni N; Tonelli M; de Vivo A; Palareti G; Tura S; Baccarani M
Haematologica; 2004 Jul; 89(7):826-31. PubMed ID: 15257934
[TBL] [Abstract][Full Text] [Related]
6. Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation.
Awan FT; Osman S; Kochuparambil ST; Gibson L; Remick SC; Abraham J; Craig M; Jillella A; Hamadani M
Bone Marrow Transplant; 2012 Jan; 47(1):146-8. PubMed ID: 21358681
[No Abstract] [Full Text] [Related]
7. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield.
Breitkreutz I; Lokhorst HM; Raab MS; Holt Bv; Cremer FW; Herrmann D; Glasmacher A; Schmidt-Wolf IG; Blau IW; Martin H; Salwender H; Haenel A; Sonneveld P; Goldschmidt H
Leukemia; 2007 Jun; 21(6):1294-9. PubMed ID: 17377586
[TBL] [Abstract][Full Text] [Related]
8. Pegylated-interferon induced severe bone marrow hypoplasia in a patient with multiple myeloma receiving thalidomide.
Gómez-Rangel JD; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
Am J Hematol; 2003 Dec; 74(4):290-1. PubMed ID: 14635214
[No Abstract] [Full Text] [Related]
9. Pulmonary hypertension and thalidomide therapy in multiple myeloma.
Hattori Y; Shimoda M; Okamoto S; Satoh T; Kakimoto T; Ikeda Y
Br J Haematol; 2005 Mar; 128(6):885-7; author reply 887-8. PubMed ID: 15755296
[No Abstract] [Full Text] [Related]
10. Severe hepatic toxicity due to thalidomide in relapsed multiple myeloma.
Trojan A; Chasse E; Gay B; Pichert G; Taverna C
Ann Oncol; 2003 Mar; 14(3):501-2. PubMed ID: 12598363
[No Abstract] [Full Text] [Related]
11. Thalidomide-induced neuropathy.
Crawford CL
Mayo Clin Proc; 2002 Dec; 77(12):1395; author reply 1395. PubMed ID: 12479531
[No Abstract] [Full Text] [Related]
12. Arterial and venous thrombotic complications with thalidomide in multiple myeloma.
Alkindi S; Dennison D; Pathare A
Arch Med Res; 2008 Feb; 39(2):257-8. PubMed ID: 18164975
[No Abstract] [Full Text] [Related]
13. Pulmonary hypertension related to thalidomide therapy in refractory multiple myeloma.
Antonioli E; Nozzoli C; Gianfaldoni G; Mannelli F; Rossi S; Betti S; Bernardeschi P; Fiorentini G; Bosi A
Ann Oncol; 2005 Nov; 16(11):1849-50. PubMed ID: 16012178
[No Abstract] [Full Text] [Related]
14. Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency.
Tosi P; Zamagni E; Tacchetti P; Ceccolini M; Perrone G; Brioli A; Pallotti MC; Pantani L; Petrucci A; Baccarani M; Cavo M
Biol Blood Marrow Transplant; 2010 Aug; 16(8):1115-21. PubMed ID: 20197100
[TBL] [Abstract][Full Text] [Related]
15. Thalidomide-induced fulminant hepatic failure.
Hamadani M; Benson DM; Copelan EA
Mayo Clin Proc; 2007 May; 82(5):638. PubMed ID: 17493431
[No Abstract] [Full Text] [Related]
16. Efficacy of thalidomide in the treatment of VAD-refractory plasma cell leukaemia appearing after autologous stem cell transplantation for multiple myeloma.
Bauduer F
Br J Haematol; 2002 Jun; 117(4):996-7. PubMed ID: 12060146
[No Abstract] [Full Text] [Related]
17. Thalidomide before autologous stem cell transplantation in VAD-refractory multiple myeloma patients.
Patriarca F; Sperotto A; Prosdocimo S; Geromin A; Zaja F; Fanin R
Haematologica; 2003 May; 88(5):597-9. PubMed ID: 12745281
[No Abstract] [Full Text] [Related]
18. Posterior reversible encephalopathy syndrome as a consequence of high dose steroid administration after autologous PBSCT.
Sukumaran S; George B; Nair HP; Drobyski WR
Bone Marrow Transplant; 2010 Apr; 45(4):779-80. PubMed ID: 19684634
[No Abstract] [Full Text] [Related]
19. Progress in the treatment of multiple myeloma.
Kumar S
Lancet; 2006 Mar; 367(9513):791-2. PubMed ID: 16530557
[No Abstract] [Full Text] [Related]
20. Pulmonary veno-occlusive disease as a cause for reversible pulmonary hypertension in a patient with multiple myeloma undergoing peripheral blood stem cell transplantation.
Malhotra P; Varma S; Varma N; Sharma RR; Jain S; Kumari S; Manoj R; Marwaha N
Am J Hematol; 2005 Oct; 80(2):164-5. PubMed ID: 16184590
[No Abstract] [Full Text] [Related]
[Next] [New Search]
